Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

Launched by FUNDACIÓN GECP ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with stage III non-small cell lung cancer, which is a type of lung cancer that has not spread to distant parts of the body but affects nearby areas in the lung. The study is testing a combination of medicines—Atezolizumab, Paclitaxel, and Carboplatin—given before any surgery to shrink the tumor and help improve outcomes. After this initial treatment, a team of doctors will review each patient’s situation to decide if surgery is a good option. Depending on that decision, patients will then receive different follow-up treatments, including ongoing Atezolizumab to help keep the cancer from coming back.

People eligible for this trial are adults aged 65 to 74 who have been diagnosed with stage IIIA or IIIB non-small cell lung cancer. During the study, participants will receive three cycles of the initial treatment combination, followed by careful monitoring and further treatment based on the doctors’ evaluation. The main goal is to see how long patients live without the cancer getting worse. The trial will last about 10 years in total, including treatment and follow-up. This study is currently recruiting patients, and it involves several hospitals working together to offer this treatment option.

Gender

ALL

Eligibility criteria